Dick,
FYI, seen this?
The shares of smaller companies are sometimes known as ‘penny shares’.
They don’t meet the requirements for a full listing on the London Stock Exchange (they’re ‘unlisted companies’), so they’re bought and sold on other markets, like the Alternative Investment Market (AIM) and the Plus Quoted Market.
If you want to sell, it can be hard to find buyers for some shares – you might be stuck with the shares, or have to sell at a much lower price than you paid for them.
There might not be much information available - so it could be hard to assess the business and its finances and predict if it will do well.
Think carefully before you invest in a small company. Is the investment right for your needs? What are the risks, and what might they mean for you?
Evening Dick,
You have now found the best place to be over on ADVFN, so perhaps best you stay there, most over there are banned over here on LSE for their crazy posting. At least LSE is perhaps over moderated to allow good folk to have discussions with minor disagreements.
Go for it, you will no doubt find like minded people there.... Enjoy
Dick,
I think you may have found us all out, maybe we should talk to our friends in Sardinia to deliver a horse to you!, haha
Really!
Most of us here rub along with many different opinions and views on this share without any sinister motives, sometimes a little heated, but that's all.
We are all invested or trading the share with many different viewpoints, simple as that really IMO.
What I think is very important is that we share our research, thoughts, opinions in order to make our own individual decisions.
ATB
Dick,
Sorry to hear you are so negative, perhaps you could read through some of the informative posts and perhaps also look at Scancell's website:-
24 June 2020
Scancell Holdings plc
(“Scancell” or the “Company”)
New publication highlights potential of Modi-1 for hard to treat cancers
Modi-1 Phase 1/2 trial expected to start in H1 2021
Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer,
is pleased to announce the publication of a peer-reviewed research paper in the Journal for
ImmunoTherapy of Cancer entitled: “Combination vaccine based on citrullinated vimentin and enolase
peptides induces potent CD4-mediated anti-tumor responses”.1 The Company also provides an update
on current progress and future plans for a Phase 1/2 clinical trial in patients with solid tumours including
triple negative breast cancer, ovarian cancer, renal cancer and head and neck cancer.
Scancell’s Moditope® platform represents a completely new class of potent and selective
immunotherapy agents based on stress-induced post-translational modifications (siPTM) such as
citrullination. The publication describes the first Moditope® vaccine, Modi-1, and its ability to stimulate
potent T cell responses that translate into tumour protection in melanoma and ovarian cancer models.
The responses were mediated by CD4 T cells and were also able to protect against a second challenge
of the tumour confirming the induction of a memory response. The paper also confirms that conjugating
the Modi-1 citrullinated peptides to the toll-like receptor-stimulating adjuvant AMPLIVANT®, previously
licensed from ISA Pharmaceuticals, allows the therapeutic dose to be reduced by up to 100-fold. The
full abstract is detailed below.
In January 2020, the Company provided an update on progress towards initiating the Modi-1 Phase 1/2
clinical trial. This has been advanced further with successful completion of GMP drug substance
manufacture for all three of the conjugates that comprise the Modi-1 product. Importantly, the technical
challenges reported in January concerning one of the peptide components have been successfully
resolved, enabling progression to GMP drug product manufacture and formulation of clinical supplies
in Q3 2020.
Formal regulatory-compliant toxicity studies have now been completed, with no evidence of any local
or systemic toxicities being reported. In addition to the Scientific Advice meeting held with the PaulEhrlich-Institut regulatory authority in 2019, a further successful meeting was held with the UK
Medicines and Healthcare products Regulatory Agency in February 2020. The Company continues to
progress the necessary processes and documentation required for regulatory submission to start the
planned clinical study in the UK in the first half of 2021.
Professor Lindy Durrant, Chief Scientific Officer of Scancell, commented:
“These data further validate the unique mode of action, and long-term prote
Evening Ruck,
Tough times for us all, seems like life is on "hold" not nice.
Just when perhaps we could enjoy the time we have worked so hard for.
Very much missing the real live banter of friends and associates.
Your life seems quite similar, I walk 2 miles twice a day with my headphones on, Bruce in the morning and Jeremy in the afternoon, that's about as good as it gets at the moment.
2020, write it off!
ATB
Take care.
ATB
C7,
You got me thinking where I would be right now... oh dinner at Alice Sweetwater in Naples, crab & lobster wantons, steamed green lip mussels, sitting outside in the sunshine, or at the Boathouse down on the water having a beautiful Rib Eye with caeser salad and anchovies, washed down with some lovely wines... then back to the pool at the house for an evening dip.
Seems like an age ago!!
Maybe next year
You would be welcome too.
ATB
Evening C7,
I agree with you about getting out and about, no quite confident about that just yet. Our local opened Monday but thought best to let the demand die down a little.
I am just about happy to have the family around, especially if we can sit out in the garden. Both my children are professionals, one a Senior Air Traffic Controller the other a Paramedic and are very mindful of my age and risk, although I am in really good shape other than a bit of BP.
Just seems that I am wasting my weeks away though sometimes.
ATB
Evening Ruck,
How was your rib eye last night , Pittsburgh style I hope (burned and turned) and as for the wine CDP it's my choice of wines
I felt like the underdog with just a wagyu burger and a few tinnies.
ATB
Ivy, Chester.
You have both summed it up really, so where to next.... win or lose I guess... that's it really.
I'll stay in the win category for now and may be proved wrong, but I can live with that.
Surely you can see the science regarding Scancell though, it is something that no other can replicate at the moment, so could be a really good gamble/investment, despite all the negative posts.
Time will tell though
ATB